Mersana Therapeutics Earnings Estimate
| MRSN Stock | USD 29.08 0.18 0.62% |
Mersana Therapeutics Earnings per Share Projection vs Actual
About Mersana Therapeutics Earnings Estimate
The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of Mersana Therapeutics earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current Mersana Therapeutics estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as Mersana Therapeutics fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.'
Please read more on our stock advisor page.| Last Reported | Projected for Next Year | ||
| Retained Earnings | -806 M | -765.7 M | |
| Retained Earnings Total Equity | -405.4 M | -385.2 M | |
| Earnings Yield | (0.45) | (0.48) | |
| Price Earnings Ratio | (2.28) | (2.39) | |
| Price Earnings To Growth Ratio | 0.05 | 0.04 |
Pair Trading with Mersana Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Mersana Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Mersana Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Mersana Stock
Moving against Mersana Stock
| 0.91 | DWTX | Dogwood Therapeutics | PairCorr |
| 0.84 | EDIT | Editas Medicine | PairCorr |
| 0.83 | ABP | Abpro Holdings Buyout Trend | PairCorr |
| 0.8 | GNLX | Genelux Common | PairCorr |
| 0.8 | IMRN | Immuron Ltd ADR | PairCorr |
The ability to find closely correlated positions to Mersana Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Mersana Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Mersana Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Mersana Therapeutics to buy it.
The correlation of Mersana Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Mersana Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Mersana Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Mersana Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in producer price index. You can also try the Stocks Directory module to find actively traded stocks across global markets.
Will Biotechnology sector continue expanding? Could Mersana diversify its offerings? Factors like these will boost the valuation of Mersana Therapeutics. Expected growth trajectory for Mersana significantly influences the price investors are willing to assign. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Mersana Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (13.95) | Revenue Per Share | Quarterly Revenue Growth (0.13) | Return On Assets | Return On Equity |
Investors evaluate Mersana Therapeutics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Mersana Therapeutics' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Mersana Therapeutics' market price to deviate significantly from intrinsic value.
Understanding that Mersana Therapeutics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Mersana Therapeutics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Conversely, Mersana Therapeutics' market price signifies the transaction level at which participants voluntarily complete trades.